SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
2.06%21.3314.1%$125.51m
MDCOMedicines Company
1.72%53.0920.3%$104.73m
GWPHGW Pharmaceuticals PLC Sponsored ADR
3.55%120.336.2%$95.99m
AMRNAmarin Corporation Plc Sponsored ADR
2.65%15.861.8%$84.76m
JAZZJazz Pharmaceuticals Plc
0.34%118.052.3%$59.26m
SAGESAGE Therapeutics, Inc.
3.54%144.268.6%$55.96m
PRGOPerrigo Co. Plc
1.45%53.826.8%$52.09m
PCRXPacira Pharmaceuticals, Inc.
4.07%38.1010.5%$45.60m
UTHRUnited Therapeutics Corporation
0.89%81.9714.3%$39.43m
CTLTCatalent Inc
1.84%49.232.4%$35.25m
HZNPHorizon Pharma plc
3.35%28.206.6%$35.07m
ICLRICON Plc
0.27%141.024.1%$32.80m
ICPTIntercept Pharmaceuticals, Inc.
5.62%64.2516.9%$32.03m
AERIAerie Pharmaceuticals, Inc.
2.92%20.286.8%$28.14m
AXSMAxsome Therapeutics, Inc.
13.10%20.632.0%$25.52m

Company Profile

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.